CannaCiencia promotes Medicinal Cannabis in the medical, scientific and business agenda of the country.

CannaCiencia promotes Medicinal Cannabis in the medical, scientific and business agenda of the country.

With close to 350 attendees, 24 presentations by experts in medicinal cannabis and a commercial space that gathered brands and enterprises at national and international level, Cannaciencia, the first Cannabis Science Symposium of the Americas is consolidated as the platform to educate, visualize advances scientists, academics, doctors, pharmacists and technologists in this field, and the challenges and opportunities for the development of the cannabis industry in Colombia.

 

The first edition of CannaCiencia leaves a good balance. The participation of world authorities such as Dr. Uma Dhanabalam, expert, activist, defender and educator of the therapeutic use of medicinal cannabis; and Dr. Sue Sisley, who has been working on the investigation of the use of cannabis in the treatment of post-traumatic stress in veterans of war in the United States, had a great reception as a reference of the advances and barriers that currently face in their exercise professional, and education as the first path to destigmatization both in the medical community and in the general imagination.

 

In this context, the educational impact is highlighted as one of the main achievements of the event, especially with the topics related to the analytical laboratory and quality control, where there was a great lack of knowledge in the country. The outstanding participation of Scott Kuzdzal, an expert in toxicology and therapeutic drug monitoring, emphasized the responsibility of the industry in the implementation of effective processes to guarantee the correct labeling and the production of safe and contaminant-free medicinal cannabis.

 

For his part, Joshua Crossney, Founder of jCanna and the Cannabis Science Conference in the USA, presented the advances in academic research, in its commitment to close the gap between analytical sciences and the medical industry of cannabis to help improve quality of the products that patients use.

 

CannaCiencia also made visible the Colombian scientists and the research they are currently carrying out, offering them a platform for discussion, interconnection and search for funding, at a point where it is crucial to promote research for medical, clinical and pharmaceutical development.

 

The context of legalization and regulation of Medicinal Cannabis in Colombia also opened a door for industry experts and investors from countries where the business is already on a journey, which focus on the opportunities and potential of the nascent local industry. The presence of important investors in Cannaciencia such as Tuatara Capital of New York, support the importance of this scenario.

 

In the same way, a new and growing generation of entrepreneurs was identified around the medicinal cannabis industry, eager for ideas, information and alternatives to access capital.

 

“We are facing the challenges of an industry that is at the starting point. The economic impact of the emerging industry worldwide is historic, with compound annual growth rates of up to 34% (CAGR). It requires a huge venture capital education (risk capital) component, clear regulation by the competent financial authorities and inclusion for the Latino community in the emerging industry worldwide, “says Carol Ortega Algarra, CEO of Muisca Capital Group, the first Latin investment management firm, Founder of CannaCiencia and the Network of Cannabis Entrepreneurs of Colombia ”

 

For his part, Ricardo Martinez Executive Director of CannaCiencia and the Network of Cannabis Entrepreneurs of Colombia, says that the 3 most outstanding results of the symposium were: advanced scientific education given to attendees, visualization of Latin American scientists and their findings , derived from research projects, and the visit of multiple investment firms and family offices in North America, Europe and Asia. CannaCiencia is positioned as an international benchmark in science related to Medicinal Cannabis.

 

As a result, in August, the first cycle of training for entrepreneurs linked to the Network of Cannabis Entrepreneurs of Colombia and individuals interested in training will begin, with the first CannaCiencia Workshop, which will include the participation of specialists in cultivation, production, transformation and economic science of medicinal cannabis.

Dr. Scott Kuzdzal: Expert in Clinical Chemistry and Clinical in Cannaciencia

Dr. Scott Kuzdzal: Expert in Clinical Chemistry and Clinical in Cannaciencia

Dr. Scott Kuzdzal gave me a series of papers that allowed me to write these lines about him. I would define him as the expert in analytical and clinical chemistry in the medicinal cannabis industry.

I will start with analytical chemistry, it is about the study of the chemical composition of a material or sample, through different methods and laboratory tests. In our case, the Medicinal Cannabis plant can have more than 500 chemical compounds that must be studied. Among those that highlight Cannabinoids, terpenoids and flavonoids, in addition to the study of the relationships and synergies that could exist between these compounds.

 

The study of the analytical chemistry of Medicinal Cannabis has been blocked for more than 80 years, with which there is a lot of delay in this field, only until they have been giving legalizations to the use of Medicinal Cannabis have begun to make these studies.

 

The medical cannabis analytical tests are in their infancy, but it has all the importance to preserve the health of the patients. The medicinal Cannabis plant is exposed to many risks since it is grown: bacteria, fungi, yeasts, molds, heavy metals, pesticides, aflatoxins, mycotoxins, is processed and packaged: residual solvents, packaging and delivered to the patient. And precise labeling is required to guarantee the safety and quality of medical cannabis to the patient.

 

A deeper step is clinical chemistry, it is about the study of the chemistry of the human body versus treatments. By means of bio-markers, the response or tolerance of a medicine is evaluated and it is revealed if the treatment is effective. This development in the case of Medicinal Cannabis can lead to a personalized medicine approach.

 

With all this evidence, Dr. Kuzdzal’s assessment is overwhelming that today there are huge and important opportunities in the medical cannabis industry for analytical and clinical chemists and they have a decisive role.

 

Dr. Kuzdzal will participate in Cannaciencia with the lecture titled, “Cannabis Analytical Testing: From Cannabinomics to Contaminomics and Beyond.” This lecture will take a closer look at cannabis QC analytical testing and discuss some of the major challenges and opportunities, including a comprehensive look at cannabis heavy metals testing. Attendees will learn about analytical technologies employed in cannabis QC testing labs, understand the limitations of current lab testing applications and take a deep dive into cannabis heavy metals testing technologies. This lecture will also present future opportunities for cannabis testing and research.

 

Source:
Unraveling the cannabinome. By Scott Kuzdzal and William Lipps.